Puma Biotechnology Q3 product revenue falls

Puma Biotechnology

06/11/2025 21:38

Overview

Puma Q3 2025 product revenue declines to $51.9 mln from $56.1 mln in Q3 2024

Puma Biotechnology reports Adjusted EPS of $0.21

Company raises full-year 2025 NERLYNX revenue and net income estimates

Outlook

Puma raises 2025 net product revenue forecast to $198–$200 mln

Company increases 2025 net income estimate to $27–$29 mln

Puma anticipates key clinical milestones for alisertib in H1 2026

Result Drivers

U.S. SALES INCREASE - Co reports 8% increase in bottles of NERLYNX sold in U.S. market, contributing to higher net selling price

OPERATING COSTS DECREASE - Total operating costs and expenses decreased significantly, aiding earnings trend

INCREASED DEMAND - CEO attributes positive earnings trend to increased demand for NERLYNX

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Product Revenue
$51.90 mln
Q3 Adjusted EPS
$0.21
Q3 EPS
$0.18
Q3 Adjusted Net Income
$10.50 mln
Q3 Net Income
$8.80 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Puma Biotechnology Inc is $4.00, about 23.6% below its November 5 closing price of $4.95

The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 7 three months ago

Press Release: ID:nBw5MstdYa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)